Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia
Rebecca Gardner(Seattle Children's Hospital), Michael C. Jensen(Seattle Children's Hospital), Kaelin Crews(Seattle Children's Hospital), Julie Rivers(Seattle Children's Hospital), Adam J. Lamble(Seattle Children's Hospital), Christopher Brown, Karen Spratt, Lauren Huang(Seattle Children's Hospital), Joshua D. Gustafson, Corinne Summers(Seattle Children's Hospital), Stephanie Mgebroff(Bloodworks Northwest), Olivia Finney(Seattle Children's Hospital), Colleen Annesley(Unknown), Catherine Lindgren(Unknown), Adam Johnson(Sana Biotechnology (United States)), Julie R. Park(Seattle Children's Hospital)
Cited by 65
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754